CN112180100A - Application of TWEAK as molecular marker for identifying different types of psoriasis - Google Patents
Application of TWEAK as molecular marker for identifying different types of psoriasis Download PDFInfo
- Publication number
- CN112180100A CN112180100A CN202011034089.5A CN202011034089A CN112180100A CN 112180100 A CN112180100 A CN 112180100A CN 202011034089 A CN202011034089 A CN 202011034089A CN 112180100 A CN112180100 A CN 112180100A
- Authority
- CN
- China
- Prior art keywords
- tweak
- serum
- psoriasis
- patients
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
Abstract
The invention discloses application of TWEAK as a molecular marker for identifying different types of psoriasis, belonging to the technical field of biological medicines. According to the invention, the functions of the TWEAK level in serum and skin lesions in diagnosis of different types of psoriasis and the relationship between the TWEAK level and other cytokines are researched to help the identification and disease condition evaluation of PV, EP and PP, so that the determination of the TWEAK in serum and skin lesion tissues is possibly helpful for identifying PV, PP and EP by combining detection means such as other cytokines and the like, and the prognosis and progress condition of psoriasis patients can be evaluated according to the change trend of the TWEAK.
Description
Technical Field
The invention belongs to the technical field of biological medicine, and relates to application of TWEAK as a molecular marker for identifying different types of psoriasis.
Background
Psoriasis is a common chronic inflammatory disease with frequent skin and joint involvement. Psoriasis is divided into several different clinical types, of which about 90% of patients with psoriasis present with Psoriasis Vulgaris (PV), also the most common type. Psoriasis Pustulosa (PP) is mainly characterized by the appearance of aseptic pustules on the skin, either locally or systemically. Erythrodermic Psoriasis (EP) is a more severe type that can occur secondary to the first two types of psoriasis. The pathogenesis of psoriasis is not fully elucidated at present, but various proinflammatory cytokines, such as TNF-alpha, IL-6, IL-17, IL-22 and many cytokine receptors are involved in the pathogenesis of psoriasis, some of which cytokines or receptors are also in the research phase as therapeutic targets.
Tumor necrosis factor-like weak apoptosis inducing factor (TWEAK) is a relatively new member of Tumor necrosis factor superfamily, and has the functions of stimulating cell growth, apoptosis, angiogenesis, regulating immune response and the like. TWEAK can regulate different inflammatory pathways and cell fates by binding to its receptor, fibroblast growth factor-induced 14 (Fn 14). TWEAK in physiological states may contribute to normal tissue regeneration and repair following acute injury, but continued activation of TWEAK leads to chronic inflammation and progressive local tissue damage.
Currently, no clear means is available for conveniently and quickly judging the clinical type of a psoriasis patient, which may cause adverse consequences caused by misjudgment during treatment, such as conversion from PV type to PP or EP, and aggravation of the patient's illness.
Disclosure of Invention
In order to overcome the drawbacks of the prior art described above, the present invention aims to provide the use of TWEAK as a molecular marker for the identification of different types of psoriasis.
In order to achieve the purpose, the invention adopts the following technical scheme to realize the purpose:
the invention discloses application of TWEAK as a molecular marker for identifying different types of psoriasis.
The invention discloses an application of a reagent for detecting TWEAK in preparing a diagnostic reagent for psoriasis.
Preferably, the diagnostic agent is a diagnostic agent that distinguishes the type of psoriasis.
Preferably, the TWEAK levels in the serum/skin lesions of EP patients are significantly higher than the TWEAK levels in the serum of PV patients, PP patients and healthy control subjects.
The invention also discloses application of the reagent for detecting TWEAK in preparing a kit for diagnosing and/or detecting psoriasis of a subject, and a method for diagnosing and/or detecting psoriasis, which comprises the following steps:
1) obtaining a biological sample to be tested: serum or skin lesions as test samples;
2) determining the presence and/or amount of TWEAK in the test sample;
3) comparing the presence and/or amount of TWEAK in the test sample relative to a reference or control sample;
4) determining whether the subject has: psoriasis.
6. Use according to claim 5, wherein an increase in the presence and/or amount of TWEAK in the serum/skin lesion relative to a reference or control sample is indicative of psoriasis.
The invention also discloses a serum diagnostic reagent for psoriasis, which comprises a commercial anti-TWEAK antibody and an ELISA plate; the TWEAK level in serum and skin lesions is detected by adopting a sandwich ELISA method, and the specific operation is as follows: adding an anti-TWEAK antibody to an enzyme label plate, incubating overnight, sealing with 3% fetal calf serum, adding a serum or urine sample diluted by 1:100 and a standard substance, and incubating; and then adding the prepared detection antibody combined with the streptavidin-horseradish peroxidase to an enzyme label plate, adding a substrate, stopping the reaction, finally reading an OD value at 450nm of an enzyme label instrument, preparing a standard curve according to the concentration of the standard substance, and calculating the concentration of the sample.
Compared with the prior art, the invention has the following beneficial effects:
according to the invention, the functions of the TWEAK level in serum and skin lesions in diagnosis of different types of psoriasis and the relationship between the TWEAK level and other cytokines are researched to help the identification and disease condition evaluation of PV, EP and PP, so that the determination of the TWEAK in serum and skin lesion tissues is possibly helpful for identifying PV, PP and EP by combining detection means such as other cytokines and the like, and the prognosis and progress condition of psoriasis patients can be evaluated according to the change trend of the TWEAK.
Drawings
FIG. 1 is a graph of results of TWEAK levels in serum of different types of psoriasis patients;
FIG. 2 shows the immunohistochemical results of skin lesions of patients with psoriasis and the expression levels of TWEAK and Fn 14; wherein a is the immunohistochemical result of TWEAK and Fn14 skin lesions in skin lesions of patients with psoriasis; b is the TWEAK expression level of different types of psoriatic lesions; c is the expression level of Fn14 for different types of psoriatic lesions;
FIG. 3 is a graph showing the results of IL-17A and IFN-. gamma.expression in serum; wherein a is IL-17A; b is IFN-gamma;
FIG. 4 is a graph showing the results of IL-22 and IL-36. gamma. expression in serum; wherein a is IL-22; b is IL-36 gamma;
FIG. 5 is a graph of the correlation results of serum TWEAK levels and serum IL-17A levels in PV patients;
FIG. 6 is a graph of the correlation results of serum TWEAK levels and serum IFN- γ levels in PV patients;
FIG. 7 is a graph showing the correlation between serum TWEAK levels and cytokine IL-36 γ;
FIG. 8 is a graph showing the correlation between serum TWEAK levels and cytokine IL-22.
Detailed Description
In order to make the technical solutions of the present invention better understood, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It should be noted that the terms "first," "second," and the like in the description and claims of the present invention and in the drawings described above are used for distinguishing between similar elements and not necessarily for describing a particular sequential or chronological order. It is to be understood that the data so used is interchangeable under appropriate circumstances such that the embodiments of the invention described herein are capable of operation in sequences other than those illustrated or described herein. Furthermore, the terms "comprises," "comprising," and "having," and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, system, article, or apparatus that comprises a list of steps or elements is not necessarily limited to those steps or elements expressly listed, but may include other steps or elements not expressly listed or inherent to such process, method, article, or apparatus.
The invention is described in further detail below with reference to the accompanying drawings:
the invention determines the functions of the TWEAK and the SLE disease activity index (SLEDAI) in the disease diagnosis and monitoring process and the guiding functions of glucocorticoid dosage, reduction and disease regression in SLE treatment by discussing the functions of serum and urine TWEAK levels in different types of lupus erythematosus diagnosis and evaluating the relationship between the TWEAK and the SLE disease activity index.
1. Experimental materials and methods
1.1 study objects and groups
A total of 36 psoriasis patients were enrolled in the study (see Table 1 for specific clinical data), of which PV20, and 8 PP and EP patients each had been discontinued at least 3 months at the time of enrollment, and were not associated with other immunological or inflammatory diseases. Healthy control 20 cases. All subjects signed written informed consent.
TABLE 1
1.2 detection of cytokines such as TWEAK in serum
TWEAK levels in serum were detected by sandwich ELISA. The specific experimental steps are as follows: anti-TWEAK antibodies (capture antibody, Cat # DY1090, R & D Systems Inc) were added to 96-well microtiter plates as described and incubated overnight. After 3% fetal calf serum was blocked, a 1:100 dilution of serum sample and standard was added and incubated. The prepared detection antibody combined by the streptavidin-horseradish peroxidase is added to an enzyme label plate, and a substrate is added to stop the reaction. And finally, reading the OD value at 450nm of the microplate reader, making a standard curve and calculating.
Serum IL-17A, IFN-gamma, IL-22 and IL-36 gamma assays were performed according to the Elabccience instructions.
1.3 immunohistochemical detection of TWEAK and Fn14
The brief steps are as follows: paraffin sections were deparaffinized, rehydrated, and endogenous peroxidase (DAKO) blocked, rabbit anti-human Fn14 antibody (ab109365) and rabbit anti-human TWEAK antibody (ab37170) were incubated at 4 ℃ for overnight incubation. And then, incubating a goat anti-rabbit IgG secondary antibody section marked by HRP, developing DAB, counterstaining with hematoxylin, observing and photographing under a mirror after mounting, and quantitatively analyzing the staining by Image J. .
2. Results of the experiment
2.1 clinical data
The experiment included 36 psoriasis patients, of which 15 women and 21 men; the patients are 9-78 years old, and the average age is 47.50 + -3.361 years old; the healthy control group comprises 20 women and 8 men, wherein the ages of the women and the men are 33-73 years old, and the average age is 52.85 +/-2.789 years old. The age (p-0.2871) and female/male ratio (p-0.1950) of psoriasis patients were not significantly different from the control group. The mean course of psoriasis is 12.9 ± 11.9(0.1-43 years). Of 36 psoriasis patients, PV20 (55.6%), PE 8 (22.2%), PP 8 (22.2%).
2.2 increase of TWEAK levels in serum and skin lesions of psoriasis and significant difference between different types of psoriasis
The results of the levels of TWEAK in the serum of patients with psoriasis (PV:376.1 ± 21.64pg/ml, PP:247.9 ± 24.73pg/ml, PE:407.8 ± 69.72pg/ml) are shown in fig. 1, and are clearly higher than those of healthy controls (34.16 ± 2.844 pg/ml; F ═ 51.32, p < 0.0001). Wherein, the TWEAK value of EP and PV serum is obviously higher than that of psoriasis pustulosa.
Immunohistochemical results of skin lesions in each group showed positive results for TWEAK and Fn14 in skin lesions of psoriatic patients (as shown in a in fig. 2). After quantification, the percentages of TWEAK and Fn14 per square millimeter of positive cells in the skin lesions of psoriasis patients were significantly higher than those of healthy controls. The positive rates of TWEAK and Fn14 were also different in different types of psoriatic lesions, with the highest positive rates of TWEAK and Fn14 in EP group, the lowest in PV group and the lowest in PP group, and the differences were statistically significant when two of the three groups were compared, suggesting that TWEAK (b in fig. 2) and Fn14 expression levels were different in different types of psoriatic lesions (c in fig. 2).
2.3 high expression of IL-17A/IFN-gamma/IL-22/IL-36 gamma in serum of patients with psoriasis
IL-17A levels in the serum of psoriasis patients were significantly higher than those of healthy controls (PV:327.4 + -71.34 pg/mL, PP:118.2 + -17.54 pg/mL, EP:131.1 + -21.41 pg/mL vs HC:68.90 + -11.92 pg/mL; F-5.677, p <0.0001) (shown in a in FIG. 3). The PV group has the highest TWEAK value in serum, and has obvious difference compared with EP and PP groups.
In addition, IFN-gamma in the serum of psoriasis patients is obviously higher than that of healthy control group (PV:87.62 +/-19.89 pg/mL, PP:41.96 +/-7.105 pg/mL, EP:57.72 +/-13.96 pg/mL vs HC:6.081 +/-0.3741 pg/mL, F is 7.192, P is 0.0003) (shown in b in figure 3). Compared with the PP group, the PV group has more obvious increase of the IFN-gamma value of the serum. Meanwhile, the expression level of IL-22 in the serum of the EP group is obviously higher than that of psoriasis patients and healthy control groups of other two groups (EP:968.3 +/-146.4 pg/mL vs HC:23.32 +/-8.075 pg/mL, PV:231.3 +/-97.37 pg/mL, PP:142.9 +/-61.36 pg/mL, F ═ 20.94, P <0.0001) (a in figure 4).
Compared with PV, PP and healthy control groups, the serum IL-36 gamma expression level of patients in the EP group is obviously increased (HC:4.089 + -0.7431 pg/mL vs PV:17.40 + -1.694 pg/mL, PP:83.68 + -25.05 pg/mL, EP:26.61 + -3.994 pg/mL, F-7.605, P-0.0002) (b in figure 4).
2.4 Positive correlation between serum TWEAK expression levels of different psoriasis patients and different cytokines
We also assessed correlations between serum TWEAK levels and other cytokine (IL-17/IFN- γ/IL-22/IL-36 γ) expression levels in patients with different types of psoriasis, with the following results:
the correlation results between the serum TWEAK levels and the serum IL-17A levels (r-0.5679, p-0.0217) in PV patients are shown in figure 5 and table 2 below:
TABLE 2
The result shows that the serum TWEAK level of the PV patient is in significant positive correlation with the serum IL-17A level;
the correlation results between the serum TWEAK level and the serum IFN- γ level (r 0.6495, p 0.0065) of PV patients are shown in fig. 6 and table 3 below:
TABLE 3
The result shows that the serum TWEAK level of the PV patient is in significant positive correlation with the serum IFN-gamma level; while the serum TWEAK levels in EP patients correlate weakly with serum IFN- γ (r 0.5341, p 0.0331);
results relating serum TWEAK levels to IL-36 γ (r-0.8412, p <0.0001) in EP patients are shown in figure 7 and table 4 below:
TABLE 4
The results indicate that serum TWEAK levels in EP patients correlate weakly with serum IL-36 γ levels.
Serum TWEAK levels and IL-22 results in EP patients are shown in figure 8 and table 5 below:
TABLE 5
The results indicate that serum TWEAK levels in EP patients are not related to IL-22.
3. Conclusion of the experiment
Our studies have shown significant increases in TWEAK expression in serum and skin lesion tissues in patients with psoriasis, with the most significant increase in TWEAK in serum and skin lesions in EP patients. Meanwhile, the levels of IL-17A, IFN-gamma, IL-22 and IL-36 gamma in the psoriasis serum of each group are also increased. Furthermore, our results show that serum TWEAK levels are positively correlated with serum IL-17A/IFN- γ in PV and serum IFN- γ/IL-36 γ in EP. However, there was no correlation between serum TWEAK levels and IL-22 in different types of psoriasis. These results suggest that TWEAK may be involved in the pathogenesis of PV and EP. The determination of TWEAK in serum and tissues, combined with other cytokine detection means, may help to identify PV, PP and EP. Some PV patients may be improperly treated and may be converted to PP or EP, and the trend of TWEAK may help to assess the outcome and progression of psoriasis patients.
The above-mentioned contents are only for illustrating the technical idea of the present invention, and the protection scope of the present invention is not limited thereby, and any modification made on the basis of the technical idea of the present invention falls within the protection scope of the claims of the present invention.
Claims (7)
- Use of TWEAK as a molecular marker for the identification of different types of psoriasis.
- 2. Application of a reagent for detecting TWEAK in preparing a diagnostic reagent for psoriasis.
- 3. The use of claim 2, wherein the diagnostic agent is a diagnostic agent that distinguishes the type of psoriasis.
- 4. The use according to claim 3, wherein the TWEAK levels in the serum/skin lesions of EP patients are significantly higher than the TWEAK levels in the serum of PV patients, PP patients and healthy control subjects.
- 5. Use of a reagent for detecting TWEAK in the manufacture of a kit for diagnosing and/or detecting psoriasis in a subject, characterized in that the method of diagnosis and/or detection comprises the steps of:1) obtaining a biological sample to be tested: serum or skin lesions as test samples;2) determining the presence and/or amount of TWEAK in the test sample;3) comparing the presence and/or amount of TWEAK in the test sample relative to a reference or control sample;4) determining whether the subject has: psoriasis.
- 6. Use according to claim 5, wherein an increase in the presence and/or amount of TWEAK in the serum/skin lesion relative to a reference or control sample is indicative of psoriasis.
- 7. A serum diagnostic reagent for psoriasis, which is characterized by comprising a commercial anti-TWEAK antibody and an enzyme label plate;the TWEAK level in serum and skin lesions is detected by adopting a sandwich ELISA method, and the specific operation is as follows: adding an anti-TWEAK antibody to an enzyme label plate, incubating overnight, sealing with 3% fetal calf serum, adding a serum or urine sample diluted by 1:100 and a standard substance, and incubating; and then adding the prepared detection antibody combined with the streptavidin-horseradish peroxidase to an enzyme label plate, adding a substrate, stopping the reaction, finally reading an OD value at 450nm of an enzyme label instrument, preparing a standard curve according to the concentration of the standard substance, and calculating the concentration of the sample.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011034089.5A CN112180100A (en) | 2020-09-27 | 2020-09-27 | Application of TWEAK as molecular marker for identifying different types of psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011034089.5A CN112180100A (en) | 2020-09-27 | 2020-09-27 | Application of TWEAK as molecular marker for identifying different types of psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112180100A true CN112180100A (en) | 2021-01-05 |
Family
ID=73943586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011034089.5A Pending CN112180100A (en) | 2020-09-27 | 2020-09-27 | Application of TWEAK as molecular marker for identifying different types of psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112180100A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114371135A (en) * | 2021-10-25 | 2022-04-19 | 孙良丹 | Evaluation system for evaluating psoriasis and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013022995A2 (en) * | 2011-08-08 | 2013-02-14 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| CN103154029A (en) * | 2010-10-05 | 2013-06-12 | 弗·哈夫曼-拉罗切有限公司 | Antibodies against human TWEAK and uses thereof |
| CN104245738A (en) * | 2012-04-05 | 2014-12-24 | 弗·哈夫曼-拉罗切有限公司 | Bispecific antibodies against human TWEAK and human IL17 and uses thereof |
| CN106370835A (en) * | 2016-08-29 | 2017-02-01 | 中山大学孙逸仙纪念医院 | Method for performing auxiliary diagnosis on psoriasis through immunohistochemical staining detection galectin-3 of in-vitro skin sample |
-
2020
- 2020-09-27 CN CN202011034089.5A patent/CN112180100A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103154029A (en) * | 2010-10-05 | 2013-06-12 | 弗·哈夫曼-拉罗切有限公司 | Antibodies against human TWEAK and uses thereof |
| WO2013022995A2 (en) * | 2011-08-08 | 2013-02-14 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| CN104245738A (en) * | 2012-04-05 | 2014-12-24 | 弗·哈夫曼-拉罗切有限公司 | Bispecific antibodies against human TWEAK and human IL17 and uses thereof |
| CN106370835A (en) * | 2016-08-29 | 2017-02-01 | 中山大学孙逸仙纪念医院 | Method for performing auxiliary diagnosis on psoriasis through immunohistochemical staining detection galectin-3 of in-vitro skin sample |
Non-Patent Citations (7)
| Title |
|---|
| DANIEL SIDLER等: "TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis", 《NATURE COMMUNICATIONS》 * |
| JUNG-YOON CHOE等: "Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus", 《INFLAMM. RES.》 * |
| OZLEM BILGIC等: "Serum levels of TWEAK in patients with psoriasis vulgaris", 《CYTOKINE》 * |
| 周振兴: "银屑病患者血液学检验指标变化特点及其对临床诊治价值的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 杨北辰等: "寻常型银屑病TWEAK/CD163在外周血中表达的初步研究", 《四川大学学报（医学版）》 * |
| 穆震: "《新编皮肤病学》", 30 June 2018, 西安交通大学出版社 * |
| 袁艳丽等: "肿瘤坏死因子超家族成员12(TNFSF12/TWEAK)在寻常型银屑病皮损组织表达增强", 《细胞与分子免疫学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114371135A (en) * | 2021-10-25 | 2022-04-19 | 孙良丹 | Evaluation system for evaluating psoriasis and application |
| CN114371135B (en) * | 2021-10-25 | 2024-01-30 | 孙良丹 | Evaluation system for evaluating psoriasis and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012021407A2 (en) | Biomarkers for stroke | |
| WO2011135024A1 (en) | Methods for detecting antibodies | |
| JP6639392B2 (en) | Method for selective measurement of placental growth factor 2 | |
| US9417249B2 (en) | Methods of predicting and decreasing the risk of pre-term birth | |
| Koshiol et al. | Circulating inflammatory proteins and gallbladder cancer: Potential for risk stratification to improve prioritization for cholecystectomy in high-risk regions | |
| EP2399133B1 (en) | Gdf15 as a differential marker for spondyloarthropathy | |
| CN112180100A (en) | Application of TWEAK as molecular marker for identifying different types of psoriasis | |
| Bieglmayer et al. | Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin | |
| CN107255711A (en) | Osteopontin is used for the purposes for preparing or screening acute-on-chronic liver failure diagnostic reagent | |
| KR101978677B1 (en) | Biomarkers for diagnosing rheumatoid arthritis | |
| JP2013213774A (en) | Biomarker for inspecting tuberculosis | |
| JP4734647B2 (en) | Diagnosis method of myasthenia gravis with thymoma | |
| CN109891241B (en) | Examination method capable of specifically diagnosing early stage disease of diabetic nephropathy | |
| Marini et al. | P649 comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients | |
| US9523690B2 (en) | Biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma | |
| JP7016110B2 (en) | Biomarker for differentiating Still's disease from sepsis | |
| CN112180082B (en) | Application of TWEAK in preparation of lupus erythematosus diagnostic reagent | |
| WO2013088140A2 (en) | Biomarker and use thereof | |
| CN111032053A (en) | DEFA 5-targeting antibodies and assays for diagnosis and treatment of inflammatory bowel disease | |
| US9377473B2 (en) | Immunoassays and methods of detecting and measuring intact fibroblast growth factor 23, and C-terminal and N-terminal fragments thereof | |
| WO2013050573A1 (en) | C-mip : a biomarker of lupus nephritis | |
| KR102638210B1 (en) | Biomarkers for the diagnosis of thyroid ophthalmopathy and uses thereof | |
| Tan et al. | The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease | |
| JP6306124B2 (en) | Tuberculosis testing biomarker | |
| Watanabe et al. | New fecal biomarker, α1-acid glycoprotein, for evaluation of inflammatory bowel disease: comparison with calprotectin and lactoferrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210105 |